IAC regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Idarubicin-Ara C-Cladribine regimen; Idarubicin-Cytarabine-Cladribine regimen
Overview
IAC regimen refers to a regimen consisting of idarubicin, cytarabine (Ara-C), and cladribine used to treat acute myelogenous leukemia.[1]
Regimen
IIdrarubicin
ACytarabine (Ara-C)
CCladribin
Indications
References
- ↑ 1.0 1.1 Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C; et al. (2003). “Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study”. Br J Haematol. 123 (5): 810–8. PMID 14632771.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH